Key result
Risk-tailored statin therapy with electronic pillboxes is cost-effective in HIV, gaining ~59,000 QALYs.
Why the study?
Is statin-based primary prevention of cardiovascular disease with electronic pillboxes cost-effective for people with HIV in China?
Is statin-based primary prevention of cardiovascular disease with electronic pillboxes cost-effective for people with HIV in China?
Effect estimate: ICER $16,799/QALY
Authors
No takes yet. Share an insight, caveat, or question.
Risk-stratified CVD prevention integrating periodic screening and tailored pharmacotherapy, with electronic pillboxes at higher healthcare investment levels, is cost-effective for people with HIV in China.
Li et al. (2026) studied HIV (n=100,000). Risk-tailored lipid-lowering therapy with electronic pillboxes vs. Status quo was evaluated on Incremental cost-effectiveness ratio (ICER) per QALY gained (ICER $16,799/QALY). Risk-tailored lipid-lowering therapy with electronic pillboxes for people with HIV in China was cost-effective at a 3×GDP threshold (ICER $16,799/QALY), gaining 59,125 QALYs versus status quo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: